Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Jorge E. Cortes, Delphine Rea, Michael J. Mauro, Andreas Hochhaus, Dong-Wook Kim, Koji Sasaki, Fabian Lang, Michael C. Heinrich, Massimo Breccia, Michael W. Deininger, Yeow Tee Goh, Jeroen J.W.M. Janssen, Moshe Talpaz, Valle Gomez G De Soria, Philipp le Coutre, Francois-Xavier Mahon, Daniel Deangelo, Shruti Kapoor, Gessami Sanchez-Olle, Meng Cao, Nithya Agrawal, Timothy P Hughes
Institutions: Augusta University, Hôpital Saint-Louis, Laboratoire d'hématologie, Memorial Sloan Kettering Cancer Center, Jena University Hospital, Eulji Medical Center, Eulji University Uijeongbu Eulji Medical Center, The University of Texas MD Anderson Cancer Center, Goethe University Frankfurt, University Hospital Frankfurt, Oregon Health & Science University, Portland VA Medical Center, VA Portland Health Care System, OHSU Knight Cancer Institute, Policlinico Umberto I, Sapienza University of Rome, Versiti Blood Center of Wisconsin, Singapore General Hospital, Radboud University Medical Center, U-M Rogel Cancer Center, Hospital Universitario de La Princesa, Charité - Universitätsmedizin Berlin, Institut Bergonié, Dana-Farber Cancer Institute, Novartis (Switzerland), South Australian Health and Medical Research Institute, The University of Adelaide
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405042857